After many years of foregoing a salary, the CEO of a D.C. internet service provider has elected to start receiving a regular ...

A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of ...

H.C. Wainwright raised the firm’s price target on Cogent Biosciences (COGT) to $52 from $50 and keeps a Buy rating on the shares. The firm sees an ...

Shares of Cogent Biosciences surged in 2025 as enthusiasm mounted over its lead drug candidate, and four top-ranking ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit. Cogent randomized ...

US fiber firm Cogent is set to sell two data centers it acquired from Sprint. In October 2025, Cogent entered into a letter of intent to sell two data centers it acquired and repurposed in connection ...

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

Cogent Biosciences, Inc. has entered into a securities purchase agreement for a private investment in public equity financing, expected to raise approximately $225 million. The financing was led by ...

Cogent Biosciences, Inc.‘s (NASDAQ:COGT) bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder. With ...

Stephen Shankland worked at CNET from 1998 to 2024 and wrote about processors, digital photography, AI, quantum computing, computer science, materials science, supercomputers, drones, browsers, 3D ...

Cogent Communications' Q2 2023 financial results show rapid expansion and significant revenue growth. The company's recent acquisitions and strategic positioning make it an attractive investment ...